SEPTIN9 and prostate carcinoma: SEPT9 has been found to be overexpressed in diverse human tumors, including breast, head and neck, ovarian, endometrial, kidney, and pancreatic cancer [31–33], and its overexpression was recently shown to correlate with high-grade breast cancer [34] and prostate cancer [35].